TickerFacts.

Replimune Group, Inc. (REPL): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$3.33M
Year ended 2026-03-31
$3.40M
Trailing 12 months to 2026-06-30
+10.8%
3-year compound annual growth
+14.3%
5-year compound annual growth
$3.50M2017-03-31: $122.0K2018-03-31: $109.0K2019-03-31: $148.0K2020-03-31: $533.0K2021-03-31: $1.71M2022-03-31: $2.15M2023-03-31: $2.45M2024-03-31: $2.65M2025-03-31: $3.50M2026-03-31: $3.33M$3.33M
2017-03-31 Depreciation & Amortization (USD) 2026-03-31
Period endedDepreciation & AmortizationChange YoYSource filing
2026-03-31$3.33M-4.9%2026-06-29, From 2025-04-01
2025-03-31$3.50M+31.9%2026-06-29, From 2024-04-01
2024-03-31$2.65M+8.5%2025-05-22, From 2023-04-01
2023-03-31$2.45M+14.0%2024-05-16, From 2022-04-01
2022-03-31$2.15M+25.5%2023-05-18, From 2021-04-01
2021-03-31$1.71M+221.0%2022-05-19, From 2020-04-01
2020-03-31$533.0K+260.1%2021-05-20, From 2019-04-01
2019-03-31$148.0K+35.8%2020-06-03, From 2018-04-01
2018-03-31$109.0K-10.7%2020-06-03, From 2017-04-01
2017-03-31$122.0Kn/a2019-06-28, From 2016-04-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Replimune Group, Inc. (REPL)2026-03-31$3.33M-4.9%
Prokidney Corp. (PROK)2025-12-31$6.58M+21.0%
Prime Medicine, Inc. (PRME)2025-12-31$7.32M+19.5%
Fate Therapeutics Inc (FATE)2025-12-31$12.90M-32.0%
C4 Therapeutics, Inc. (CCCC)2025-12-31$1.96M+7.8%
LENZ Therapeutics, Inc. (LENZ)2025-12-31$287.0K+394.8%
Scilex Holding Co (SCLX)2025-12-31$4.62M+14.3%
Kyverna Therapeutics, Inc. (KYTX)2025-12-31$1.80M-15.7%
Alector, Inc. (ALEC)2025-12-31$5.72M+5.8%

Compare REPL, PROK, PRME, FATE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗